Investigational Agents for JAKi-Refractory Myelofibrosis
October 28, 2022
https://www.targetedonc.com/view/invest ... lofibrosis
Dr. Masc at International Congress on MPN
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Re: Dr. Masc at International Congress on MPN
Ryan - Nice dig! Thanks for the link. It seems as we close in on ASH physicians/clinicians are becoming more public and vocal on new treatment alternatives.
Of the three highlighted alternative treatments here, only one stands out as having the highest safety profile, while focusing on Overall Survival (OS)........
Navtemadlin (Kartos Therapeutics):
"...hematologists/oncologists have encountered serious toxicity, specifically gastrointestinal (GI) toxicity. Because of the safety/tolerability profile of navtemadlin, other agents in the same class may offer better results, explained Mascarenhas."
Bomedemstat (Imago Biosciences):
"....bomedemstat administered once daily is safe and improves symptom burden, spleen size, and anemia in patients with advanced MF"......
..."Serious cases of thrombocytopenia were observed during the study."
Imetelstat (Geron):
..."In the 107 patients treated with imetelstat in the study, the median OS was 29.9 months. There was a bone marrow fibrosis improvement in 40.5% and variant allele frequency reduction of driver mutations in 42.1% of evaluable patients."......
...."the most common adverse events (AEs) in both treatment arms were grade 3 or 4 cytopenia. All AEs in the study were reversible."
CONCLUSION: ...."I think our goal should focus on its survival benefits. We need to move on beyond slated symptoms and start improving survival in patients with this disease,” Mascarenhas concluded."
***Talk about a subtle endorsement.....
Dr. Mascarenhas concludes this article with the statement above. Only ONE of the above treatments (Imetelstat) in this article mentions Overall Survival (OS) in their profile. -Kmall
Of the three highlighted alternative treatments here, only one stands out as having the highest safety profile, while focusing on Overall Survival (OS)........
Navtemadlin (Kartos Therapeutics):
"...hematologists/oncologists have encountered serious toxicity, specifically gastrointestinal (GI) toxicity. Because of the safety/tolerability profile of navtemadlin, other agents in the same class may offer better results, explained Mascarenhas."
Bomedemstat (Imago Biosciences):
"....bomedemstat administered once daily is safe and improves symptom burden, spleen size, and anemia in patients with advanced MF"......
..."Serious cases of thrombocytopenia were observed during the study."
Imetelstat (Geron):
..."In the 107 patients treated with imetelstat in the study, the median OS was 29.9 months. There was a bone marrow fibrosis improvement in 40.5% and variant allele frequency reduction of driver mutations in 42.1% of evaluable patients."......
...."the most common adverse events (AEs) in both treatment arms were grade 3 or 4 cytopenia. All AEs in the study were reversible."
CONCLUSION: ...."I think our goal should focus on its survival benefits. We need to move on beyond slated symptoms and start improving survival in patients with this disease,” Mascarenhas concluded."
***Talk about a subtle endorsement.....
Dr. Mascarenhas concludes this article with the statement above. Only ONE of the above treatments (Imetelstat) in this article mentions Overall Survival (OS) in their profile. -Kmall